(Q31367335)
Statements
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes (English)
A Venditti
A Tamburini
F Buccisano
M T Scimò
G Del Poeta
L Maurillo
M C Cox
M Tribalto
M Masi